Wu Ben J, Li Yue, Ong Kwok L, Sun Yidan, Shrestha Sudichhya, Hou Liming, Johns Douglas, Barter Philip J, Rye Kerry-Anne
From the School of Medical Sciences, The University of New South Wales Sydney, Australia (B.J.W., K.L.O., Y.S., S.S., L.H., P.J.B., K.-A.R.); Institute of Pathophysiology and Immunology, Medical University of Graz, Austria (Y.S.); and Merck & Co., Inc, Kenilworth, NJ (D.J.).
Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2333-2341. doi: 10.1161/ATVBAHA.117.310051. Epub 2017 Oct 12.
Angioplasty and stent implantation, the most common treatment for atherosclerotic lesions, have a significant failure rate because of restenosis. This study asks whether increasing plasma high-density lipoprotein (HDL) levels by inhibiting cholesteryl ester transfer protein activity with the anacetrapib analog, des-fluoro-anacetrapib, prevents stent-induced neointimal hyperplasia.
New Zealand White rabbits received normal chow or chow supplemented with 0.14% (wt/wt) des-fluoro-anacetrapib for 6 weeks. Iliac artery endothelial denudation and bare metal steel stent deployment were performed after 2 weeks of des-fluoro-anacetrapib treatment. The animals were euthanized 4 weeks poststent deployment. Relative to control, dietary supplementation with des-fluoro-anacetrapib reduced plasma cholesteryl ester transfer protein activity and increased plasma apolipoprotein A-I and HDL cholesterol levels by 53±6.3% and 120±19%, respectively. Non-HDL cholesterol levels were unaffected. Des-fluoro-anacetrapib treatment reduced the intimal area of the stented arteries by 43±5.6% (<0.001), the media area was unchanged, and the arterial lumen area increased by 12±2.4% (<0.05). Des-fluoro-anacetrapib treatment inhibited vascular smooth muscle cell proliferation by 41±4.5% (<0.001). Incubation of isolated HDLs from des-fluoro-anacetrapib-treated animals with human aortic smooth muscle cells at apolipoprotein A-I concentrations comparable to their plasma levels inhibited cell proliferation and migration. These effects were dependent on scavenger receptor-B1, the adaptor protein PDZ domain-containing protein 1, and phosphatidylinositol-3-kinase/Akt activation. HDLs from des-fluoro-anacetrapib-treated animals also inhibited proinflammatory cytokine-induced human aortic smooth muscle cell proliferation and stent-induced vascular inflammation.
Inhibiting cholesteryl ester transfer protein activity in New Zealand White rabbits with iliac artery balloon injury and stent deployment increases HDL levels, inhibits vascular smooth muscle cell proliferation, and reduces neointimal hyperplasia in an scavenger receptor-B1, PDZ domain-containing protein 1- and phosphatidylinositol-3-kinase/Akt-dependent manner.
血管成形术和支架植入是治疗动脉粥样硬化病变最常用的方法,但由于再狭窄,其失败率较高。本研究旨在探讨使用阿那曲泊帕类似物去氟阿那曲泊帕抑制胆固醇酯转运蛋白活性来提高血浆高密度脂蛋白(HDL)水平是否能预防支架诱导的内膜增生。
新西兰白兔接受普通饲料或添加0.14%(重量/重量)去氟阿那曲泊帕的饲料喂养6周。在去氟阿那曲泊帕治疗2周后,进行髂动脉内皮剥脱和裸金属支架植入。支架植入后4周对动物实施安乐死。与对照组相比,补充去氟阿那曲泊帕的饮食降低了血浆胆固醇酯转运蛋白活性,使血浆载脂蛋白A-I和HDL胆固醇水平分别升高了53±6.3%和120±19%。非HDL胆固醇水平未受影响。去氟阿那曲泊帕治疗使支架置入动脉的内膜面积减少了43±5.6%(<0.001),中膜面积未改变,动脉管腔面积增加了12±2.4%(<0.05)。去氟阿那曲泊帕治疗使血管平滑肌细胞增殖抑制了41±4.5%(<0.001)。将来自去氟阿那曲泊帕治疗动物的分离HDL与人主动脉平滑肌细胞在与其血浆水平相当的载脂蛋白A-I浓度下孵育,可抑制细胞增殖和迁移。这些作用依赖于清道夫受体-B1、含PDZ结构域的衔接蛋白1和磷脂酰肌醇-3-激酶/蛋白激酶B(PI3K/Akt)的激活。去氟阿那曲泊帕治疗动物的HDL还可抑制促炎细胞因子诱导的人主动脉平滑肌细胞增殖和支架诱导的血管炎症。
在新西兰白兔中,通过抑制胆固醇酯转运蛋白活性并造成髂动脉球囊损伤和植入支架,可提高HDL水平,抑制血管平滑肌细胞增殖,并以清道夫受体-B1、含PDZ结构域的衔接蛋白1和PI3K/Akt依赖的方式减少内膜增生。